bovhyaluronidase azoximer improved exercise tolerance and reduced breathlessness in post-COVID-19 patients.

Faster lung recovery was noted in those with cardiovascular issues after 180 days.

“Arthritis drugs already available for prescription have the potential to halt lingering lung problems that can last months or years after COVID-19 infections, new research from the University of Virginia School of Medicine and Cedars-Sinai suggests.

By examining damaged human lungs and developing an innovative new lab model, the scientists identified faulty immune processes responsible for the ongoing lung issues that plague an increasing number of people after they've otherwise recovered from COVID-19. These lasting harms of COVID infection, known as ‘post-infection lung fibrosis,’ have no good treatments. The new research, however, suggests that existing drugs such as baricitinib and anakinra can disrupt the malfunctioning immune response and finally allow damaged lungs to heal.”

“My lungs aged 19 years after having COVID.

After 18 months and numerous interventions, my lungs still have not regained full capacity.

• In 2021, my lung capacity was age 26.
• By Nov 2022, after getting covid, my lung capacity was age 45.
• Now 2024, my lung capacity is age 37.

My covid symptoms were very mild and lasted only 3 days. Lung therapies below.”

Horrific: Covid double lung transplant:

'This is terrible looking lungs my god look it's like a bomb'

Not new but this study neatly illustrates the vascular nature of acute #COVID lung disease.

The image shows small blood vessels (red) at the edges of the lungs are shut down & bigger vessels (blue) in the central lungs are enlarged.

#COVIDISNOTPNEUMONIA